Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Exagen (XGN) EBT (2018 - 2025)

Exagen's EBT history spans 8 years, with the latest figure at -$4.7 million for Q4 2025.

  • For Q4 2025, EBT fell 24.3% year-over-year to -$4.7 million; the TTM value through Dec 2025 reached -$19.9 million, down 31.76%, while the annual FY2025 figure was -$19.9 million, 31.76% down from the prior year.
  • EBT reached -$4.7 million in Q4 2025 per XGN's latest filing, up from -$7.1 million in the prior quarter.
  • In the past five years, EBT ranged from a high of -$3.0 million in Q2 2024 to a low of -$15.1 million in Q4 2022.
  • Average EBT over 5 years is -$6.7 million, with a median of -$5.9 million recorded in 2021.
  • Peak YoY movement for EBT: plummeted 128.86% in 2022, then soared 65.83% in 2023.
  • A 5-year view of EBT shows it stood at -$6.9 million in 2021, then plummeted by 119.79% to -$15.1 million in 2022, then skyrocketed by 63.35% to -$5.5 million in 2023, then soared by 32.33% to -$3.7 million in 2024, then decreased by 24.3% to -$4.7 million in 2025.
  • Per Business Quant, the three most recent readings for XGN's EBT are -$4.7 million (Q4 2025), -$7.1 million (Q3 2025), and -$4.4 million (Q2 2025).